Free Trial

Allspring Global Investments Holdings LLC Sells 6,577 Shares of Regeneron Pharmaceuticals, Inc. $REGN

Regeneron Pharmaceuticals logo with Medical background

Key Points

  • Allspring Global Investments Holdings LLC has reduced its holdings in Regeneron Pharmaceuticals, Inc. by 16.6%, selling 6,577 shares during the second quarter, leaving them with 33,053 shares valued at approximately $17.68 million.
  • Several institutional investors have increased their stakes in Regeneron, with notable increases from Pacer Advisors Inc. (2,296.9% increase) and Goldman Sachs Group Inc. (18.0% increase), while institutional ownership now stands at 83.31%.
  • Regeneron Pharmaceuticals recently announced a quarterly dividend of $0.88, reflecting an annualized yield of 0.6% and a payout ratio of 8.87%.
  • Interested in Regeneron Pharmaceuticals? Here are five stocks we like better.

Allspring Global Investments Holdings LLC decreased its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 16.6% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 33,053 shares of the biopharmaceutical company's stock after selling 6,577 shares during the period. Allspring Global Investments Holdings LLC's holdings in Regeneron Pharmaceuticals were worth $17,680,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also made changes to their positions in REGN. Nuveen LLC bought a new position in shares of Regeneron Pharmaceuticals during the first quarter valued at approximately $343,764,000. Pacer Advisors Inc. increased its stake in shares of Regeneron Pharmaceuticals by 2,296.9% during the first quarter. Pacer Advisors Inc. now owns 407,370 shares of the biopharmaceutical company's stock valued at $258,366,000 after purchasing an additional 390,374 shares in the last quarter. Goldman Sachs Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 18.0% during the first quarter. Goldman Sachs Group Inc. now owns 1,143,093 shares of the biopharmaceutical company's stock valued at $724,984,000 after purchasing an additional 174,056 shares in the last quarter. Vanguard Group Inc. increased its stake in shares of Regeneron Pharmaceuticals by 1.3% during the first quarter. Vanguard Group Inc. now owns 9,407,891 shares of the biopharmaceutical company's stock valued at $5,966,767,000 after purchasing an additional 121,545 shares in the last quarter. Finally, Retirement Systems of Alabama increased its stake in shares of Regeneron Pharmaceuticals by 476.4% during the first quarter. Retirement Systems of Alabama now owns 131,382 shares of the biopharmaceutical company's stock valued at $83,326,000 after purchasing an additional 108,589 shares in the last quarter. Institutional investors own 83.31% of the company's stock.

Analysts Set New Price Targets

A number of equities analysts have weighed in on the stock. Royal Bank Of Canada raised their target price on shares of Regeneron Pharmaceuticals from $688.00 to $695.00 and gave the company a "sector perform" rating in a research note on Monday, August 4th. Morgan Stanley cut their price target on shares of Regeneron Pharmaceuticals from $761.00 to $756.00 and set an "overweight" rating on the stock in a report on Friday, October 10th. Truist Financial cut their price target on shares of Regeneron Pharmaceuticals from $940.00 to $812.00 and set a "buy" rating on the stock in a report on Monday, August 11th. Argus cut shares of Regeneron Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Monday, June 30th. Finally, BMO Capital Markets increased their price target on shares of Regeneron Pharmaceuticals from $600.00 to $640.00 and gave the company an "outperform" rating in a report on Monday, August 4th. Three analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating, seven have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $817.88.

View Our Latest Report on Regeneron Pharmaceuticals

Regeneron Pharmaceuticals Trading Up 1.6%

Shares of REGN stock opened at $578.05 on Friday. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $1,002.69. The company has a current ratio of 4.60, a quick ratio of 3.72 and a debt-to-equity ratio of 0.09. The firm's 50 day moving average is $574.64 and its 200 day moving average is $562.89. The stock has a market capitalization of $61.27 billion, a P/E ratio of 14.57, a P/E/G ratio of 1.77 and a beta of 0.31.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last issued its earnings results on Friday, August 1st. The biopharmaceutical company reported $12.89 earnings per share (EPS) for the quarter, topping the consensus estimate of $8.43 by $4.46. Regeneron Pharmaceuticals had a net margin of 31.37% and a return on equity of 15.06%. The company had revenue of $3.68 billion for the quarter, compared to analysts' expectations of $3.30 billion. During the same quarter last year, the company posted $11.56 earnings per share. The firm's quarterly revenue was up 3.6% on a year-over-year basis. Research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Wednesday, September 3rd. Investors of record on Monday, August 18th were issued a $0.88 dividend. The ex-dividend date was Monday, August 18th. This represents a $3.52 annualized dividend and a yield of 0.6%. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is currently 8.87%.

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.

Featured Stories

Institutional Ownership by Quarter for Regeneron Pharmaceuticals (NASDAQ:REGN)

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Should You Invest $1,000 in Regeneron Pharmaceuticals Right Now?

Before you consider Regeneron Pharmaceuticals, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Regeneron Pharmaceuticals wasn't on the list.

While Regeneron Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.